Categories: News

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

Aggregated presentation by day and by market

Purchases of own shares from June 10th to 14th  2024
             
Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 10/06/2024 FR0010259150 5 000 122,0351 XPAR
IPSEN 549300M6SGDPB4Z94P11 11/06/2024 FR0010259150 7 000 122,0734 XPAR
IPSEN 549300M6SGDPB4Z94P11 12/06/2024 FR0010259150 1 863 123,2022 XPAR
IPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 6 355 123,9046 XPAR
IPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 3 442 123,5264 CEUX
IPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 203 123,3000 TQEX
IPSEN 549300M6SGDPB4Z94P11 14/06/2024 FR0010259150 6 000 120,9126 XPAR
IPSEN 549300M6SGDPB4Z94P11 14/06/2024 FR0010259150 2 000 120,7543 CEUX
      TOTAL 31 863 122,3620  

Attachment

Staff

Share
Published by
Staff
1 year ago

Recent Posts

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…

4 hours ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…

4 hours ago

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…

4 hours ago

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…

4 hours ago

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

4 hours ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

4 hours ago